PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Stomach neoplasm

Drugs in development · updated 30 October 2026

Stomach neoplasm: drugs in development

As of 30 October 2026 there are 378 active clinical trials (recruiting or ongoing, phases I–III) on 340 drugs for stomach neoplasm. 239 are experimental, that is not yet approved in the United States.

378Active trials
239Experimental drugs
24Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
SintilimabSinitilimab, SindilimabII–III29NCT06977061
ApatinibRivoceranibIII16NCT06346392
Disitamab VedotinRC48-ADC, Disitamb VedotinII–III10NCT05980481
CadonilimabAK104, CandonilimabII–III9NCT06221748
RilvegostomigAZD2936III8NCT07431281
CamrelizumabCarrelizumab, CarilizumabIII5NCT04342910
[18F]FAPI-74II–III4NCT07018661
AZD0901III4NCT06346392
BalstilimabBalstililmab, BalstilmabIII3NCT06346197
Sonesitatug VedotinIII3NCT07431281
TegafurIII3NCT05914610
Tegafur-gimeracil-oteracil potassiumTeysuno®III3NCT07818070
BotensilimabIII2NCT06346197
ONO-4578III2NCT07818070
PumitamigII–III2NCT07221149
BL-M05D1III1NCT07518147
EnvolimabIII1NCT05914610
EvorpaceptALX148II–III1NCT05002127
GEH300079II–III1NCT07219238
HLX22III1NCT06532006
IAH0968II–III1NCT06504732
KN026II–III1NCT05427383
PF-08634404II–III1NCT07392892
PlacboII–III1NCT05427383
SerplulimabHLX10, Hetronifly®II9NCT07902648
AdebrelimabSHR-1316, AdebelimabI–II7NCT06776770
Retlirafusp alfaSHR-1701II7NCT07904442
QL1706I–II4NCT07453394
TuvonralimabII4NCT07595523
IparomlimabiparomilimabII3NCT07595523
IvonescimabAK112II3NCT07070466
SHR-A1811II3NCT07110571
SHR-A1904II3NCT07110571
VolrustomigMEDI5752II3NCT05489211
CT041I–II2NCT04581473
CVL237II2NCT07446049
ElironrasibRMC-6291I–II2NCT06128551
Izalontamab brengitecanBL-B01D1, BMS-986507II2NCT06008054
LM-302II2NCT06519591
PucotenlimabHX008II2NCT07692334

Sorted by most advanced phase and number of active trials. Showing 40 of 239 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
OxaliplatinOxaliplatine, OxaliplainII–III71NCT05980481
CapecitabineXeloda, Capectitabine TabletsII–III42NCT05980481
PembrolizumabKEYTRUDA, MK-3475III40NCT06093425
Fluorouracil5-Fluorouracil, AdrucilII–III34NCT06028737
PaclitaxelTaxol, PaxlitaxelII–III30NCT05002127
DocetaxelTaxotere, Beizray®II–III26NCT06028737
NivolumabOpdivo, ONO-4538II–III26NCT07392892
LeucovorinFolinic acid, l-leucovorinII–III23NCT06028737
TislelizumabTisleizumab, TiselizumabIII21NCT05152147
TrastuzumabHerceptin, tratuzumabII–III18NCT06504732
IrinotecanOnivyde, CPT-11II–III16NCT05427383
CisplatinCis Platinum, CisplatineII–III15NCT01924819
FruquintinibFruquinitinib, Fruzaqla®II–III10NCT06977061
Trastuzumab deruxtecanDS-8201a, DS-8201III10NCT06731478
RamucirumabCyramza®II–III9NCT05002127

Sorted by most advanced phase and number of active trials. Showing 15 of 101 drugs.

All 340 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D013274 “Stomach Neoplasms”.

ItalianoFrançaisDeutsch